Mounjaro (Tirzepatide for T2D)

Mounjaro is Eli Lilly's brand name for tirzepatide for type 2 diabetes. FDA-approved 2022. The first dual GIP/GLP-1 receptor agonist. Weekly subcutaneous injection.

At a glance

• Generic name: tirzepatide
• FDA-approved indication: Type 2 diabetes (2022)
• Manufacturer: Eli Lilly
• List price (cash, no coverage): ~$1,069/month
• Insurance coverage: Most commercial plans cover for T2D

What Mounjaro is and isn't

Mounjaro and Zepbound contain the same active ingredient (tirzepatide) but are different products with different FDA-approved indications. Mounjaro is for T2D; Zepbound is for chronic weight management and (since December 2024) for moderate-to-severe OSA in adults with obesity. See Mounjaro vs Zepbound.

Dosing

• Start: 2.5 mg weekly × 4 weeks.
• Titration: 5 → 7.5 → 10 → 12.5 → 15 mg.
• Maintenance: 5–15 mg weekly.

Clinical trials

SURPASS program — head-to-head studies including SURPASS-3 (tirzepatide superior to titrated insulin degludec on A1c and weight). See research bibliography. SURPASS-CVOT cardiovascular outcomes reads out 2026.

Cost

List ~$1,069/month. With insurance for T2D: typical copay $25–$100/month. Compounded tirzepatide cash-pay is substantially lower ($186–$269/mo) — see tirzepatide page.

See also

· All about tirzepatide · Mounjaro vs Zepbound · Drug interactions